Characteristics | II group (n = 28) | CI group (n = 23) | Statistics | P |
---|---|---|---|---|
Demographics | Â | Â | Â | Â |
 Gender (male), n (%) | 20 (71.4) | 16 (69.6) | 0.021 | 0.884 |
 Age (y), mean ± SD | 70.2 ± 17.1 | 72.1 ± 17.1 | 0.634 | 0.529 |
 Body weight (kg), mean ± SD | 59.8 ± 11.1 | 61.6 ± 7.0 | 0.722 | 0.474 |
 Height (cm), median [IQR] | 170.0 (157.0,174.0) | 170.0 (161.5, 172.3) | − 0.162 | 0.872 |
Assessment scores | Â | Â | Â | Â |
 APACHE II | 24.8 ± 8.8 | 22.8 ± 6.0 | 0.443 | 0.666 |
 SOFA | 10.7 ± 3.5 | 9.3 ± 2.5 | 0.694 | 0.508 |
Comorbidities, n (%) | Â | Â | Â | Â |
 Cerebral infarction | 8 (28.6) | 5 (21.7) | 0.310 | 0.577 |
 Craniocerebral injury | 7 (25.0) | 3 (13.0) | 0.512 | 0.474 |
 Hypertension | 15 (53.6) | 12 (52.2) | 0.010 | 0.921 |
 Diabetes | 9 (32.1) | 7 (30.4) | 0.017 | 0.896 |
 Congestive heart failure | 11 (39.3) | 8 (34.8) | 0.110 | 0.741 |
 Atrial fibrillation | 4 (14.3) | 6 (26.1) | 0.493 | 0.483 |
 COPD | 1 (3.6) | 2 (8.7) | NA | 0.583 |
Complications, n (%) | Â | Â | Â | Â |
 Respiratory failure | 22 (78.6) | 17 (73.9) | 0.152 | 0.696 |
 Septic shock | 20 (71.4) | 14 (60.9) | 0.634 | 0.426 |
Laboratory values at baseline | Â | Â | Â | Â |
 Albumin (g/L), mean ± SD | 30.9 ± 5.3 | 32.8 ± 3.4 | 1.659 | 0.101 |
 ALT (U/L), median [IQR] | 25.0 (16.5, 44.3) | 24.0 (18.8, 40.8) | − 0.191 | 0.848 |
 Creatinine (μmol/L), median [IQR] | 153.8 (79.6, 313.0) | 151.7 (50.8, 197.0) | − 0.858 | 0.391 |
Laboratory values on the last day of vancomycin administration | Â | Â | Â | Â |
 Albumin (g/L), median [IQR] | 32.4 (26.7, 37.0) | 33.1 (30.0, 36.0) | − 1.015 | 0.310 |
 ALT (U/L), median [IQR] | 21.0 (14.0, 34.3) | 26.5 (15.5, 39.0) | − 0.910 | 0.363 |
 Creatinine (μmol/L), median [IQR] | 122.5 (64.8, 283.0) | 128.1 (79.6, 196.1) | − 0.288 | 0.774 |
Dosage regimen | Â | Â | Â | Â |
 Daily dose (mg/kg), median [IQR] | 21.4 (12.0, 29.6) | 16.7 (14.2,26.5) | − 0.395 | 0.693 |
 Duration (d), median [IQR] | 10.0 (8.0, 12.0) | 8.0 (6.8, 14.0) | − 0.819 | 0.413 |
Concomitant antibiotic therapy, n (%) | 20 (71.4) | 16 (69.6) | 0.021 | 0.884 |
 Carbapenems | 12 (60.0) | 11 (68.8) | 0.731 | 0.882 |
 β-Lactamase inhibitor compound | 5 (25.0) | 4 (25.0) | ||
 Ceftazidime | 3 (15.0) | 1 (6.3) | ||
 Antifungal agents | 3 (15.0) | 3 (18.8) | NA |  > 0.999 |
Sites of infection, n (%) | Â | Â | Â | Â |
 Lung | 26 (92.9) | 20 (87.0) | 0.497 | 0.481 |
 Bloodstream | 3 (10.7) | 3 (13.0) | NA |  > 0.999 |
 Urinary tract | 4 (14.3) | 1 (4.4) | 0.51 | 0.475 |
 Intra-abdominal | 1 (3.6) | NA | NA |  > 0.999 |
 Skin and soft-tissue | 4 (14.3) | NA | NA |  > 0.999 |
 Infective endocarditis | 1 (3.6) | 2 (8.7) | 0.032 | 0.857 |
 ≥ 2 sites of infection | 14 (50.0) | 6 (26.1) | 3.029 | 0.082 |
Microbiology, n (%) | Â | Â | Â | Â |
 MRSA | 9 (50.0) | 11 (61.1) | 2.115 | 0.861 |
 Enterococcus faecium | 5 (27.8) | 4 (22.2) | ||
 Staphylococcus epidermidis | 1 (5.6) | 2 (11.1) | ||
 Staphylococcus haemolyticus | 2 (11.1) | 1 (5.6) | ||
 Staphylococcus hominis | 1 (5.6) | NA | ||
 ≥ 2 kinds of Gram-positive bacteria | 2 (7.1) | NA | NA | 0.495 |
 Gram-negative bacteria, n (%) | 19 (67.9) | 14 (60.9) | 0.270 | 0.603 |
 Fungus | 3 (10.7) | 3 (13.0) | NA |  > 0.999 |
Vancomycin MIC values, n (%) | Â | Â | Â | Â |
 ≤ 1 mg/L | 13 (81.3) | 16 (88.9) | NA | 0.648 |
 2 mg/L | 3 (18.8) | 2 (11.1) | NA | 0.648 |